TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

William M Sikov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.